ArticleInternational journal of cardiology. Cardiovascular risk and prevention2025
Circulating-free DNA and myocardial infarction: From diagnostic promise to clinical translation.
Article in International journal of cardiology. Cardiovascular risk and prevention, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biological basis and clinical translation prospects of circulating cell-free DNA in precision management of breast cancer (Review).Oncology letters · 2026Review
- Immuno-inflammatory-metabolic interactions in cardiovascular diseases: a review from basic mechanisms to clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This correspondence responds to the review by Rafiei et al. on circulating-free DNA (cfDNA) as a biomarker for early detection of myocardial infarction (MI). CfDNA shows potential for rapid diagnosis and real-time monitoring, but major barriers remain. Lack of standardized testing methods, uncertain utility in emergency care, and high costs risk delaying adoption and widening health inequities, particularly in low- and middle-income countries (LMICs). Key priorities include harmonizing laboratory protocols, developing point-of-care platforms, and integrating cfDNA into diagnostic algorithms with cardiac troponins and electrocardiograms (ECG). Research should focus on large, long-term cohorts that include diverse populations, and test multi-marker strategies combining cfDNA with microRNAs and DNA methylation profiles. Ensuring affordability and accessibility will be critical to translate cfDNA from experimental promise to routine cardiovascular practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.